Healthcare Industry News: Herceptin
News Release - January 8, 2007
NCCN Updates Antiemesis GuidelinesJENKINTOWN, Pa.--(HSMN NewsFeed)--The National Comprehensive Cancer Network (NCCN) is pleased to announce updates to the NCCN Antiemesis Guidelines. The NCCN Clinical Practice Guidelines in Oncology(TM) are used extensively by managed care companies and by Medicare as the basis for coverage policies.
The guidelines have a new recommendation for breakthrough treatment for chemotherapy-induced nausea/vomiting. Nabilone (Cesamet, Valeant) is now recommended for breakthrough treatment.
The guidelines table describing the emetogenic potential of different antineoplastic agents has been revised. Bortezomib (Velcade, Millennium), dasatinib (Sprycel, Bristol Myers-Squibb), decitabine (Dacogen, MGI Pharma), lenalidomide (Revlimid, Celgene), nelarabine (Arranon, GlaxoSmithKline), sorafenib (Nexavar, Bayer Pharmaceuticals), sunitinib (Sutent, Pfizer), thalidomide (Thalomid, Celgene), and trastuzumab (Herceptin, Genentech) are all now considered to have minimal emetic risk.
Metoclopramide (Reglan, Baxter) and diphenhydramine (Benadryl, Parke Davis) are no longer recommended for delayed emesis prevention for patients receiving moderate-emetic-risk chemotherapy.
NCCN Clinical Practice Guidelines in Oncology(TM) are developed and updated through a consensus-driven process with explicit review of the scientific evidence by multidisciplinary panels of expert physicians from NCCN member institutions. The most recent version of this and all the guidelines are available free of charge at www.nccn.org.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 20 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN member institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.
The NCCN member institutions are: City of Hope Cancer Center, Los Angeles, CA; Dana-Farber/Brigham & Women's Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Comprehensive Cancer Center, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; Arthur G. James Cancer Hospital & Richard J. Solove Research Institute at The Ohio State University, Columbus, OH; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Memorial Sloan-Kettering Cancer Center, New York, NY; H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida, Tampa, FL; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children's Research Hospital/University of Tennessee Cancer Institute, Memphis, TN; Stanford Comprehensive Cancer Center, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UCSF Comprehensive Cancer Center, San Francisco, CA; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; UNMC Eppley Cancer Center at The Nebraska Medical Center, Omaha, NE; and The University of Texas M. D. Anderson Cancer Center, Houston, TX.
For more information, visit www.nccn.org.
Source: National Comprehensive Cancer Network
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.